Bortezomib Injection

Bortezomib Injection Specification

Indication
Multiple Myeloma, Mantle Cell Lymphoma

Origin
India

Salt Composition
Bortezomib 2 mg/vial

Dosage Form
Injection

Ingredients
Bortezomib, Mannitol

Application
Oncology, Hospital, Clinical Use

Fermentation Smell
Odorless

Storage Instructions
Store below 25°C, Protect from light

Shelf Life
24 Months

Strength
2 mg/vial

Available strength variants
2 mg, 3.5 mg

Route of Administration
Intravenous or Subcutaneous

Packaging Type
Single Use Glass Vial

Prescription/Non Prescription
Prescription

Regulatory Status
Approved by Various Regulatory Authorities

Storage Condition After Reconstitution
Refrigerate 2C to 8C; Use within 8 hours

Solubility
Soluble after reconstitution with sterile water or saline

USP Compliance
Yes

ATC Code
L01XX32

Reconstitution
Required before administration with 0.9% Sodium Chloride

Bortezomib Injection Trade Information

Supply Ability
100 Pieces Per Week

Delivery Time
1 Week

About Bortezomib Injection

Bortezomib:-

Bortezomib is used to treat people with multiple myeloma (a type of cancer of the bone marrow) who have already been treated with at least one other medication. Bortezomib is also used to treat people with mantle cell lymphoma (a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other medication. Bortezomib is in a class of medications called antineoplastic agents. It works by killing cancer cells.

Bortezomib comes as a solution (liquid) to inject into a vein. Bortezomib is given by a doctor or nurse in a medical office or clinic. It is usually given on a rotating schedule that alternates 2 weeks when bortezomib is given twice a week with 10 days when the medication is not given. During the weeks that bortezomib is given, doses will always be at least 72 hours apart. The rotating schedule may be followed for up to eight cycles. After that, your doctor may decide to continue your treatment, but you will receive bortezomib less often.

Quick and Effective Cancer Therapy

Bortezomib Injection, available in a convenient 2 mg single-use vial, provides an efficient option for oncology clinics and hospitals. Its effectiveness in treating multiple myeloma and mantle cell lymphoma makes it a preferred choice for healthcare professionals managing complex cancer cases. The straightforward reconstitution process and established regulatory approvals further ensure its reliability for clinical use.

Safe Storage and Handling

This product requires careful handling and storage for optimal results. Keep the vials below 25C and shield them from light. Once reconstituted, the solution must be refrigerated (2C to 8C) and used within 8 hours. These guidelines help preserve the integrity and potency of the medication, ensuring the highest standards in patient care.

FAQs of Bortezomib Injection:

Q: How should Bortezomib Injection 2 mg/vial be prepared before administration?

A: Bortezomib Injection must be reconstituted with 0.9% sodium chloride to achieve proper solubility. The solution should be prepared immediately prior to use and must be handled in a sterile environment for safe intravenous or subcutaneous administration.

Q: What are the main clinical indications for Bortezomib Injection?

A: Bortezomib Injection is primarily indicated for the treatment of multiple myeloma and mantle cell lymphoma. It is approved for use in hospital and clinical oncology settings by various regulatory authorities.

Q: When should the reconstituted Bortezomib Injection be used, and how should it be stored?

A: After reconstitution, Bortezomib Injection should be stored in a refrigerator at 2C to 8C and must be used within 8 hours. Any unused solution after this period should be discarded to ensure patient safety.

Q: Where is Bortezomib Injection manufactured, and does it comply with international standards?

A: This product is manufactured in India and is USP compliant. It is supplied by reputable dealers, distributors, exporters, suppliers, traders, and wholesalers, and is approved by various regulatory authorities.

Q: What benefits does Bortezomib Injection offer for oncology treatment?

A: Bortezomib provides targeted therapy for patients with certain types of cancers, potentially improving treatment outcomes in multiple myeloma and mantle cell lymphoma. Its established safety and efficacy profile make it a valuable component in cancer management.

Q: How should Bortezomib Injection be stored before and after reconstitution?

A: Before reconstitution, store the vial below 25C and protect it from light. After reconstitution with sterile saline, keep the solution refrigerated (2C to 8C), and use it within 8 hours.